Extended Zerlasiran Data Show Sustained Lp(a) Reduction

The experimental siRNA agent led to prolonged Lp(a) reduction of more than 90%, extended data from the phase 1 trial show, supporting the move to phases 2 and 3 trials.
Medscape Medical News

source https://www.medscape.com/viewarticle/extended-zerlasiran-data-show-sustained-lp-reduction-2024a10006zm?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?